PATENT CLAIM ANALYSIS

Application Number: 16071510
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-03
Patent Classification: ["424", "204100"]

Abstract:
The present invention relates to novel vaccines against malaria infections, based on recombinant adenovirus vectors. Described are capsid modified replication deficient adenovirus particle encoding and displaying circumsporozoite (CS) protein NANP-repeats (CS short ) from a malaria-causing parasite, preferably  P. falciparum,  via a minor capsid protein IX and encoding a heterologous protein as a transgene. In a particular embodiment, said replication incompetent vectors of rare serotypes such as human adenovirus 35 (HAdV35) and human adenovirus 26 (HAdV26) comprise nucleic acid encoding the CS protein, as a transgene, from a malaria-causing parasite and encoding and displaying the NANP-repeat from a malaria-causing parasite (1) directly fused to the protein IX, (2) fused to protein IX via a flexible linker or (3) an alpha-helical viral origin spacer SP1 to ensure both humoral and cellular responses against the selected antigens.

Claim (Index 14):
The method of  claim 13 , wherein the booster vaccine comprises a different vector from the first administration.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 95.0
- Lexical Diversity: 1.81609
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12928044', '13823581', '11143986', '11975396', '11607366']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6952639028053547
- 35 USC 102 Novelty (BERT): 0.504136231080115
- Combined Prediction Score: 0.6761511356328307
- Mean Citation Score: 193.457812
- Max Citation Score: 201.17903
- Similarity Product: 130.80905339196326

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test